Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Russian
  • Portuguese

Breadcrumb

  1. Home
  2. Microbiota 14 - December 2021
  3. Gut microbiota # 14
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
General Medicine

Breadcrumb

  1. Home
  2. Microbiota 14 - December 2021
  3. Gut microbiota # 14
Gastroenterology

Gut microbiota # 14

Fecal transplant

By Pr. Markku Voutilainen
Turku University Faculty of Medicine; Turku University Hospital, Department of Gastroenterology, Turku, Finland

Gastroenterology
Gynecology
Pediatrics
General Medicine
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail

Sections

Press review 14_gut microbiota

About this article

Author

Voutilainen Markku Prof Markku Voutilainen
Created 15 December 2021
Updated 12 August 2024

FECAL MICROBIOTA TRANSPLANTATION AND FIBER SUPPLEMENTATION TO CONTROL METABOLIC SYNDROME IN OBESE PERSONS

Mocanu V, Zhang Z, Deehan EC, et al. Fecal microbial transplantation patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial. Nat Med 2021; 27: 1272 -9

Obesity and metabolic syndrome (MS) comprise one of the greatest health epidemics of the 21st century. MS is associated with increased risk of cardiovascular diseases and all-cause mortality. To establish FMT as a pragmatic therapy for obesity and metabolic syndrome, novel strategies using non-invasive delivery methods in patients suffering metabolic dysfunction are needed. The authors tested oral FMT and dietary fibres supplementation to improve insulin sensitivity. In this double-blind randomized phase II trial, 70 severely obese patients with MS were randomized in four groups. The 1st and 2nd groups received single-dose oral encapsulated FMT followed by high-fermentable (HF) or low-fermentable fiber (LF) supplement for 6 weeks, respectively. The 3rd and 4th group received placebo and HF or LF supplementation. The primary outcome was the evaluation of changes in insulin sensitivity between baseline and after 6 weeks of treatment using the homeostatic model assessment (HOMA2-IR/IS). No serious adverse effects were reported during the intervention. After 6 weeks, insulin sensitivity improved only in the FMTLF group insulin levels also improved, but fasting glycemia, glycated haemoglobin and anthropometric values did not change. FMT resulted increased gut microbial richness, the change was greatest in the FMT-LF group. Phascolarcobacterium, Bacteroides stercoris and B. caccae were associated with HOMA2-IR and insulin sensitivity and may be used for future treatment.

GUT MICROBIOTA, EPITHELIAL DEFENCE AND NEONATAL BACTERIAL MENINGITIS

Travier L, Alonso M, Andronico A, et al. Neonatal susceptibility to meningitis results from the immaturity of epithelial barriers and gut microbiota. Cell Rep 2021; 35(13): 109319.

Group B streptococcus (GBS) is a leading cause of meningitis, pneumonia and sepsis in infants, and 68% of GBS neonatal meningitis are late-onset infections (developing from 7 days to 3 months after birth). This infection may result from intestinal GBS colonization transmitted from mother to child during pre- or post-delivery. The authors examined in mice the reasons of neonatal susceptibility to GBS and showed that it was associated with gut microbiota dependent/independent factors as well as age. Mature gut microbiota resists GBS colonization, strengthens gut barrier function limiting GBS invasion and plays a central role in the maturation of immune system. In neonatal gut, age-dependent Wnt pathway activity in intestinal and choroid plexus epithelia favors GBS translocation due to lower cell-cell junctions polarization. Moreover, gut microbiota immaturity is associated with decreased resistance to GBS colonization and increased vascular-gut barrier permeability, which favors bacteremia. The authors suggest that maturing neonatal microbiota with probiotics and/or prebiotics may help in preventing neonatal bacterial meningitis. In conclusion, fluoroquinolone prophylaxis gives short-term protection against infections but does not increase the risk of cross-resistance to other antibiotics.

MICROBIOTA, STRESS AND SOCIAL BEHAVIOUR

Wu WL, Adame MD, Liou CW, et al. Microbiota regulate social behavior via stress response neurons in the brain. Nature 2021; 595(7867): 409-14.

The microbiota-gut-brain axis (MGBA) is a two-way communication system linking the gut microbiota and brain. MGBA modulates behavior such as sociability and anxiety in mice, however underlying mechanisms remains unknown. In this article, antibiotic-treated mice and germ-free mice showed decreased social activity associated with increased corticosterone level. This stress hormone is produced by the activation of the hypothalamus–pituitary–adrenal axis (HPA). Gut bacteria transplantation from SPF (Specific Pathogen-Free) mice donors corrected social activity and lowered corticosterone level. Glucocorticoid receptors in the hypothalamus were negative regulators of the HPA axis These receptors regulated corticosterone levels and social behaviors, both of these functions were regulated by gut microbiota. In antibiotic-treated mice, genetic ablation of glucocorticoid receptors or chemogenetic inactivation of neurons producing the corticotrophin-releasing hormone (CRH) induce social behaviour reversal. Activation of CRH and glucocorticoid receptor-expressing neurons induced social behavior alterations in mice having normal microbiota, indicating neural pathway regulating social behavior. Finally, neomycin-sensitive bacteria, e. g. Enterococcus faecalis, mediates social behavior. The present results suggest that specific bacteria prevent overactive stress reaction by attenuating corticosterone production mediated by HPA-axis. The detection of neural pathway mediating signals from the gut to the brain may enable procedures that modulate social behavioral disorders.

GUT MICROBIOTA AND BRAIN INFARCT

Zhu W, Romano KA, Li L, et al. Gut microbes impact stroke severity via trimethylamine N-oxide pathway. Cell Host Microbe 2021; 29(7): 1199-1208.e5.

Clinical studies reported that circulating gut-microbiota derived metabolite trimethylamine- N-oxide (TMAO) are associated with stroke. However, the direct involvement of gut microbiota in cerebral vascular diseases (including stroke) is not known with certainty. Circulating TMAO is generated by microbial metabolism of TMA-containing precursors, including choline, which is commonly enriched in a Western diet. By using rodent models of stroke, the authors investigated whether gut microbiota in general or either TMAO or a functioning gut microbial cutC gene (choline utilisation [cut] c gene catalyzes choline-TMA transformation) can impact stroke severity. Germ-free mice were colonized with human gut microbiota from subjects with high or low serum TMAO levels followed by experimental stroke injury. The authors showed that stroke severity was transmissible, and TMAO levels correlated with stroke severity. Specific gut bacterial taxa positively correlate with high TMAO levels, brain infarct size through dietary choline. Gut microbial cutC gene increases host TMAO levels, cerebral infarct size, and functional deficits. In summary, gut microbiota with choline- TMAO pathway increases stroke severity and worsens functional outcome. Western diet (and diet rich in red meat) contains TMA precursors and have been associated with stroke risk. Dietary interventions in patients with high stroke risk merit further investigation. CutC activity is the key factor for stroke severity and TMAO pathway could be a potential target for the prevention or treatment of stroke.

Tags
Brain Microbiome Flora
    Focus
    Microbiota 14 - December 2021
    • Overview
      • Plausibility of a pathophysiological role for altered gut microbiota in the irritable bowel syndrome
      • Could the gut microbiome be targeted to optimize Sars-CoV-2 vaccine efficacy?
    • Commented article
      • Gut-microbiota-targeted diets modulate human immune status
      • Ethnicity associations with food sensitisation are mediated by gut microbiota development in the first year of life
    • Congress Review
      • Highlights from the APDW 2021
      • Highlights from the UEG WEEK 2021
    • Press Review
      • Gut microbiota # 14
      • Vaginal microbiota # 14
    Created 15 December 2021
    Updated 12 August 2024

    About this article

    To know more about this topic.

    Main topic

    Fecal transplant

    Content type

    Press review

    Author

    Voutilainen Markku Prof Markku Voutilainen
    Highlights from the UEG WEEK 2021
    Vaginal microbiota # 14
    Focus

    Microbiota 14 - December 2021

    Overview

    Plausibility of a pathophysiological role for altered gut microbiota in the irritable bowel syndrome Could the gut microbiome be targeted to optimize Sars-CoV-2 vaccine efficacy?

    Commented article

    Gut-microbiota-targeted diets modulate human immune status Ethnicity associations with food sensitisation are mediated by gut microbiota development in the first year of life

    Congress Review

    Highlights from the APDW 2021 Highlights from the UEG WEEK 2021

    Press Review

    Gut microbiota # 14 Vaginal microbiota # 14
    Gastroenterology
    Actu PRO : Malnutrition : agir sur le microbiote pour améliorer la croissance, un prototype à l’essai
    08.07.2021

    Malnutrition: acting on the microbiota in order to improve growth, a trial prototype

    Read the article
    07.05.2025

    The microbial-metabolic nexus in colon cancer

    Read the article
    07.02.2025

    Your functional dyspepsia diagnosis check list

    Read the article
    17.04.2025

    Sensitivity to the additive E466: the role of the microbiota

    Read the article
    Photo HCPs: Clinical context over quick fix: the fresh consensus on microbiome testing
    11.04.2025

    Clinical context over quick fix: the fresh consensus on microbiome testing

    Read the article
    22.11.2023

    Is vaginal microbiota transfer the new miracle for C-section babies?

    Read the article
    Actu PRO : Alcoolisme : expliquer les troubles sociaux grâce au microbiote
    27.01.2021

    Alcoholism: explaining social disorders thanks to the microbiota

    Read the article

    Association between fungal dysbiosis and environment

    The fungal portion of the gut microbiota (or mycobiota) has been much less studied than the bacterial...

    Find out more
    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine
    • English
    • Français
    • Español
    • Russian
    • Portuguese

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    14.05.2025

    Towards worldwide redefinition of healthy vaginal microbiota

    Read the article
    07.05.2025

    The microbial-metabolic nexus in colon cancer

    Read the article
    02.05.2025

    A new lens on chlamydia: beyond behavior, into the microbiome

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    © 2025 Biocodex. All rights reserved.

    • Legal notice
    • GTU
    • Data protection policy
    • Sitemap
    • Cookies settings
    • Digital accessibility : partially compliant
    Biocodex logo